Financial reports
ARS
2023 FY
Annual report to shareholders
4 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
11 Mar 24
8-K
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
27 Feb 24
8-K
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
8 Nov 23
8-K
Other Events
1 Sep 23
8-K
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 23
8-K
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
3 May 23
8-K
REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
28 Feb 23
8-K
Regenxbio Announces Senior Leadership Promotions
10 Jan 23
8-K
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
3 Nov 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
8 Mar 24
FWP
Free writing prospectus
7 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
1 Sep 23
S-3ASR
Automatic shelf registration
4 Aug 23
S-8
Registration of securities for employees
28 Feb 23
S-3ASR
Automatic shelf registration
30 Dec 22
S-8
Registration of securities for employees
1 Mar 22
S-8
Registration of securities for employees
1 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 22
DEF 14A
Definitive proxy
7 Apr 22
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEF 14A
Definitive proxy
19 Apr 21
PRE 14A
Preliminary proxy
8 Apr 21
DEFA14A
Additional proxy soliciting materials
8 Apr 20
Other
SEC STAFF
SEC staff action: Order
29 Mar 21
SEC STAFF
SEC staff action: Order
1 Mar 21
SEC STAFF
SEC staff action: Order
30 Sep 19
SEC STAFF
SEC staff action: Order
23 Sep 19
CT ORDER
Confidential treatment order
3 Apr 19
CT ORDER
Confidential treatment order
16 May 18
CT ORDER
Confidential treatment order
23 Mar 17
EFFECT
Notice of effectiveness
6 Jan 17
CORRESP
Correspondence with SEC
4 Jan 17
CT ORDER
Confidential treatment order
27 Dec 16
Ownership
4
Kenneth T. Mills
17 Apr 24
4
Vittal Vasista
21 Mar 24
4
Kenneth T. Mills
18 Mar 24
4
STEVE PAKOLA
7 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Kenneth T. Mills
16 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
GIC Private Ltd
5 Feb 24
SC 13G/A
JPMORGAN CHASE & CO
25 Jan 24